

Press Release

LIFE SCIENCES PARTNERS (LSP) ATTRACTS CSFB TO ITS THIRD FUND

Amsterdam and Munich, January 10, 2006

Life Sciences Partners (LSP), the pan-European venture capital group, today announces the addition of Credit Suisse First Boston Advisory Partners (CSFB) of New York to its third fund, LSP III. CSFB is recognized as one of the most respected investors in the venture capital and private equity industries. "We feel proud to have attracted such a highly respected Limited Partner to our fund." said Martijn Kleijwegt, Managing Partner at LSP. "Investors are realizing that life science venture capital can create attractive returns, as proven by three successful exits of LSP portfolio companies this year: two IPOs, DevGen (Euronext) and Jerini (Frankfurt), as well as the \$210 m trade sale of KuDOS to AstraZeneca earlier this month".

LSP III is a venture capital fund dedicated to life science investments in Europe, with a focus on the Benelux and Germany. All major investors of the previous LSP funds committed to LSP III, including, among others, the European Investment Fund (EIF), Residex and DSM. In addition to CSFB, the fund also received commitments from a number of new investors, among others from Swiss Re Private Equity Holding and Proventure. The current investor base originates from the Benelux, Germany, Switzerland, Finland and the United States of America. LSP III will invest in 15 to 20 companies active in the life science area in the Benelux, Germany and the rest of Europe, consistent with the strategy of its previous funds. LSP III already has four later stage investments in the portfolio: Octoplus (NL), Jerini (G), Idea AG (G) and Zealand Pharma (DK). These investments all have a short term exit horizon. Jerini went public on the Frankfurt stock exchange in October of this year and is comfortably trading above the listing price.

Based in Amsterdam and Munich, LSP has successfully invested in the human life sciences for over 15 years. Since inception, LSP's management has invested in 40 life science companies, of which 15 have successfully completed their IPO or merged with leading companies in the industry.

Specific examples include Crucell, KuDOS, Qiagen, Rhein Biotech (now Berna Biotech), and Pharming. With a strong management team and an extensive scientific and financial network, LSP currently has €250 million in capital under management. By carefully balancing risks, adding value as a lead investor and taking board responsibility in its portfolio companies, LSP has established itself among the leading life science investors in Europe.

LSP is advised by Matrix Private Funds Group (London), Triago (Paris and New York) and Talamore Group (Philadelphia).

For further information, please contact:

Martijn Kleijwegt
Managing Partner
Life Sciences Partners
Tel: +31 20 664 5500
Email: mkleijwegt@lspvc.com
www.lspvc.com